当前位置: 首页 >> 检索结果
7083. Subnational mapping of under-5 and neonatal mortality trends in India: the Global Burden of Disease Study 2000-17.
India has made substantial progress in improving child survival over the past few decades, but a comprehensive understanding of child mortality trends at disaggregated geographical levels is not available. We present a detailed analysis of subnational trends of child mortality to inform efforts aimed at meeting the India National Health Policy (NHP) and Sustainable Development Goal (SDG) targets for child mortality.
7085. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.
作者: Lucio Verdoni.;Angelo Mazza.;Annalisa Gervasoni.;Laura Martelli.;Maurizio Ruggeri.;Matteo Ciuffreda.;Ezio Bonanomi.;Lorenzo D'Antiga.
来源: Lancet. 2020年395卷10239期1771-1778页
The Bergamo province, which is extensively affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic, is a natural observatory of virus manifestations in the general population. In the past month we recorded an outbreak of Kawasaki disease; we aimed to evaluate incidence and features of patients with Kawasaki-like disease diagnosed during the SARS-CoV-2 epidemic.
7092. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study.
作者: Amitava Banerjee.;Laura Pasea.;Steve Harris.;Arturo Gonzalez-Izquierdo.;Ana Torralbo.;Laura Shallcross.;Mahdad Noursadeghi.;Deenan Pillay.;Neil Sebire.;Chris Holmes.;Christina Pagel.;Wai Keong Wong.;Claudia Langenberg.;Bryan Williams.;Spiros Denaxas.;Harry Hemingway.
来源: Lancet. 2020年395卷10238期1715-1725页
The medical, societal, and economic impact of the coronavirus disease 2019 (COVID-19) pandemic has unknown effects on overall population mortality. Previous models of population mortality are based on death over days among infected people, nearly all of whom thus far have underlying conditions. Models have not incorporated information on high-risk conditions or their longer-term baseline (pre-COVID-19) mortality. We estimated the excess number of deaths over 1 year under different COVID-19 incidence scenarios based on varying levels of transmission suppression and differing mortality impacts based on different relative risks for the disease.
7094. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
作者: Ivan Fan-Ngai Hung.;Kwok-Cheung Lung.;Eugene Yuk-Keung Tso.;Raymond Liu.;Tom Wai-Hin Chung.;Man-Yee Chu.;Yuk-Yung Ng.;Jenny Lo.;Jacky Chan.;Anthony Raymond Tam.;Hoi-Ping Shum.;Veronica Chan.;Alan Ka-Lun Wu.;Kit-Man Sin.;Wai-Shing Leung.;Wai-Lam Law.;David Christopher Lung.;Simon Sin.;Pauline Yeung.;Cyril Chik-Yan Yip.;Ricky Ruiqi Zhang.;Agnes Yim-Fong Fung.;Erica Yuen-Wing Yan.;Kit-Hang Leung.;Jonathan Daniel Ip.;Allen Wing-Ho Chu.;Wan-Mui Chan.;Anthony Chin-Ki Ng.;Rodney Lee.;Kitty Fung.;Alwin Yeung.;Tak-Chiu Wu.;Johnny Wai-Man Chan.;Wing-Wah Yan.;Wai-Ming Chan.;Jasper Fuk-Woo Chan.;Albert Kwok-Wai Lie.;Owen Tak-Yin Tsang.;Vincent Chi-Chung Cheng.;Tak-Lun Que.;Chak-Sing Lau.;Kwok-Hung Chan.;Kelvin Kai-Wang To.;Kwok-Yung Yuen.
来源: Lancet. 2020年395卷10238期1695-1704页
Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir-ritonavir, and ribavirin for treating patients with COVID-19.
7095. COVID-19: PCR screening of asymptomatic health-care workers at London hospital.
作者: Thomas A Treibel.;Charlotte Manisty.;Maudrian Burton.;Áine McKnight.;Jonathan Lambourne.;João B Augusto.;Xosé Couto-Parada.;Teresa Cutino-Moguel.;Mahdad Noursadeghi.;James C Moon.
来源: Lancet. 2020年395卷10237期1608-1610页 7099. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
作者: Iain B McInnes.;Frank Behrens.;Philip J Mease.;Arthur Kavanaugh.;Christopher Ritchlin.;Peter Nash.;Jordi Gratacós Masmitja.;Philippe Goupille.;Tatiana Korotaeva.;Alice B Gottlieb.;Ruvie Martin.;Kevin Ding.;Pascale Pellet.;Shephard Mpofu.;Luminita Pricop.; .
来源: Lancet. 2020年395卷10235期1496-1505页
Head-to-head trials in psoriatic arthritis are helpful in guiding clinical decision making. The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab as first-line biological monotherapy for 52 weeks in patients with active psoriatic arthritis, with a musculoskeletal primary endpoint of American College of Rheumatology (ACR) 20 response.
7100. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis.
作者: Mauro Chiarito.;Jorge Sanz-Sánchez.;Francesco Cannata.;Davide Cao.;Matteo Sturla.;Cristina Panico.;Cosmo Godino.;Damiano Regazzoli.;Bernhard Reimers.;Raffaele De Caterina.;Gianluigi Condorelli.;Giuseppe Ferrante.;Giulio G Stefanini.
来源: Lancet. 2020年395卷10235期1487-1495页
Antiplatelet therapy is recommended among patients with established atherosclerosis. We compared monotherapy with a P2Y12 inhibitor versus aspirin for secondary prevention.
|